
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group
Keywords: Ruholitinib; Hydroxyurea; Interferon; JAK2 mutation; Polycythemia vera; Ruxolitinib